Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Dr. Seymour on the Efficacy Ibrutinib Versus Chemoimmunotherapy in Older Patients With CLL

October 7th 2020

Erlene Seymour, MD, discusses the use of ibrutinib versus chemoimmunotherapy in older patients with untreated chronic lymphocytic leukemia.

Dr. Davids on the Use of Chemoimmunotherapy in CLL

October 6th 2020

Matthew S. Davids, MD, MMSc, discusses the use of chemoimmunotherapy in patients with chronic lymphocytic leukemia.

Dr. Bhat on the Combination of Ibrutinib Plus FCR in Treatment-Naïve CLL

October 5th 2020

Seema A. Bhat, MD, discusses the combination of ibrutinib plus fludarabine, cyclophosphamide, and rituximab in young patients with treatment-naïve CLL.

Dr. Bhat on the Role of Targeted Therapies in CLL

October 2nd 2020

Seema A. Bhat, MD, hematologist, discusses the role of targeted therapies in chronic lymphocytic leukemia.

The Role of Chemoimmunotherapy Dwindles Among New Regimens in Frontline CLL

September 28th 2020

Although frontline chemoimmunotherapy regimens have been the gold standard for patients with chronic lymphocytic leukemia for many years, the advent of BTK inhibitors and other novel drugs has moved the field toward adopting chemotherapy-free options for patients in this setting.

Dr. Ma on the Utility of BTK Inhibitors in Relapsed/Refractory CLL

September 24th 2020

Shuo Ma, MD, PhD, discusses the utility of BTK inhibitors in relapsed/refractory chronic lymphocytic leukemia.

Dr. Seymour on the PFS Benefit With Acalabrutinib With or Without Obinutuzumab in CLL

September 24th 2020

Erlene Seymour, MD, discusses the progression-free survival benefit with acalabrutinib with or without obinutuzumab in chronic lymphocytic leukemia.

Ibrutinib Plus Short‐Course Fludarabine Elicits Encouraging CR Rates in Previously Untreated CLL

September 23rd 2020

Christopher Pleyer, MD, discusses the phase 2 trial examining fludarabine plus ibrutinib in CLL and SLL, the next steps for the research, and where future efforts should be focused.

Dr. Seymour on the Kinase Selectivity of BTK Inhibitors in CLL

September 22nd 2020

Erlene Seymour, MD, discusses the kinase selectivity of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Woyach on Clinical Trials Examining Novel Triplets in CLL

September 14th 2020

Jennifer Woyach, MD, discusses clinical trials examining novel triplet regimens in chronic lymphocytic leukemia.

Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies

September 14th 2020

Nilanjan Ghosh, MD, PhD, discusses approved BTK inhibitors in B-cell malignancies.

Dr. Woyach on the Safety of Acalabrutinib Versus Ibrutinib in CLL

September 11th 2020

Jennifer Woyach, MD, discusses the safety profile of acalabrutinib compared with ibrutinib in chronic lymphocytic leukemia.

Acalabrutinib Shows Sustained Superiority Over Standard-of-Care Regimens in Relapsed/Refractory CLL

September 11th 2020

Acalabrutinib continued to show prolonged progression-free survival with a favorable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia, including those with high-risk features.

Ibrutinib Plus Rituximab Approved in Europe for Frontline CLL

September 10th 2020

The European Commission has approved an expanded indication of ibrutinib for use in combination with rituximab in treatment-naïve adult patients with chronic lymphocytic leukemia.

Dr. Woyach on the Role of Acalabrutinib in CLL

September 10th 2020

Jennifer Woyach, MD, discusses the role of acalabrutinib in chronic lymphocytic leukemia.

Dr. Ghosh on Unanswered Questions With BTK Inhibitors in CLL/SLL

September 10th 2020

Nilanjan Ghosh, MD, PhD, discusses remaining questions with BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Ofatumumab to Be Available Through a Patient Access Program for CLL

September 10th 2020

Patients with chronic lymphocytic leukemia who are being treated with ofatumumab will soon have to get their therapy through an oncology patient access program, as Novartis will no longer be selling the drug commercially for this indication.

Dr. Woyach on Remaining Sequencing Questions in CLL

September 9th 2020

Jennifer Woyach, MD, discusses remaining sequencing questions within the field of chronic lymphocytic leukemia.

Dr. Flinn on the Design of a Phase 2 Trial of Zanubrutinib in CLL/SLL

August 31st 2020

Ian W. Flinn, MD, PhD, discusses the design of a phase 2 trial evaluating zanubrutinib in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Building on Current Understandings of BTK Inhibition in CLL, MCL

August 19th 2020

Nilanjan Ghosh, MD, PhD, discusses the role of BTK inhibitors in B-cell malignancies and ongoing research with each agent.